BACKGROUND: There is a paucity of global data on cardiovascular disease (CVD) prevalence in people with type 2 diabetes (T2D). The primary objective of the CAPTURE study was to estimate the prevalence of established CVD and its management in adults with T2D across 13 countries from five continents. Additional objectives were to further characterize the study sample regarding demographics, clinical parameters and medication usage, with particular reference to blood glucose-lowering agents (GLAs: glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors) with demonstrated cardiovascular benefit in randomized intervention trials. METHODS: Data were collected from adults with T2D managed in primary or specialist care in Australia, China, Japan, Czech Republic, France, Hungary, Italy, Argentina, Brazil, Mexico, Israel, Kingdom of Saudi Arabia, and Turkey in 2019, using standardized methodology. CVD prevalence, weighted by diabetes prevalence in each country, was estimated for the overall CAPTURE sample and participating countries. Country-specific odds ratios for CVD prevalence were further adjusted for relevant demographic and clinical parameters. RESULTS: The overall CAPTURE sample included 9823 adults with T2D (n = 4502 from primary care; n = 5321 from specialist care). The overall CAPTURE sample had median (interquartile range) diabetes duration 10.7 years (5.6-17.9 years) and glycated hemoglobin 7.3% (6.6-8.4%) [56 mmol/mol (49-68 mmol/mol)]. Overall weighted CVD and atherosclerotic CVD prevalence estimates were 34.8% (95% confidence interval [CI] 32.7-36.8) and 31.8% (95% CI 29.7-33.8%), respectively. Age, gender, and clinical parameters accounted for some of the between-country variation in CVD prevalence. GLAs with demonstrated cardiovascular benefit were used by 21.9% of participants, which was similar in participants with and without CVD: 21.5% and 22.2%, respectively. CONCLUSIONS: In 2019, approximately one in three adults with T2D in CAPTURE had diagnosed CVD. The low use of GLAs with demonstrated cardiovascular benefit even in participants with established CVD suggested that most were not managed according to contemporary diabetes and cardiology guidelines. Study registration NCT03786406 (registered on December 20, 2018), NCT03811288 (registered on January 18, 2019).

Aix Marseille University INSERM INRA C2VN Marseille France

Centro de Atención E Investigación Cardiovascular del Potosí San Luis Potosí Mexico

Centro de Atención Integral en Diabetes Endocrinología Y Metabolismo Chacabuco Buenos Aires Argentina

Department of Clinical and Experimental Medicine Policlinico Universitario University of Messina Messina Italy

Department of Endocrinology and Metabolism Faculty of Medicine Erciyes University Kayseri Turkey

Department of Endocrinology and Metabolism Peking University 3rd Hospital Beijing China

Diabetes Unit Department of Endocrinology and Metabolism Hadassah Medical Center Faculty of Medicine Hebrew University of Jerusalem Hadassah Hebrew University Hospital PO Box 12000 91120 Jerusalem Israel

Diabetologická Interní Ambulance S R O Ostrava Czech Republic

H E C Science Clinic Yokohama Japan

Instituto de Ciencias Farmaceuticas Goiânia Goiás Brazil

King Saud University King Saud University Medical City Riyadh Kingdom of Saudi Arabia

Medical School University of Western Australia Fremantle Hospital Fremantle Australia

Novo Nordisk A S Søborg Denmark

Novo Nordisk Health Care AG Zurich Switzerland

University of Szeged Szeged Hungary

Zobrazit více v PubMed

Gerstein HC. Diabetes: dysglycaemia as a cause of cardiovascular outcomes. Nat Rev Endocrinol. 2015;11:508–510. doi: 10.1038/nrendo.2015.118. PubMed DOI

International Diabetes Federation: IDF Diabetes Atlas, 9th edn. Brussels, Belgium: International Diabetes Federation; 2019.

Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–2222. doi: 10.1016/S0140-6736(10)60484-9. PubMed DOI PMC

Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41. doi: 10.1056/NEJMoa1008862. PubMed DOI PMC

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323. doi: 10.1093/eurheartj/ehz486. PubMed DOI

American Diabetes Association 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44:S125–50. doi: 10.2337/dc21-S010. PubMed DOI

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e563–e595. PubMed PMC

Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2018;2020(43):487–493. PubMed PMC

Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62:3–16. doi: 10.1007/s00125-018-4711-2. PubMed DOI

Weng W, Tian Y, Kong SX, Ganguly R, Hersloev M, Brett J, et al. The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States. Endocrinol Diabetes Metab. 2019;2:e00076. doi: 10.1002/edm2.76. PubMed DOI PMC

Rungby J, Schou M, Warrer P, Ytte L, Andersen GS. Prevalence of cardiovascular disease and evaluation of standard of care in type 2 diabetes: a nationwide study in primary care. Cardiovasc Endocrinol. 2017;6:145–151. doi: 10.1097/XCE.0000000000000135. PubMed DOI PMC

Pugliese G, Solini A, Bonora E, Orsi E, Zerbini G, Fondelli C, et al. Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovasc Diabetol. 2014;13:59. doi: 10.1186/1475-2840-13-59. PubMed DOI PMC

Gjelsvik B, Tran AT, Berg TJ, Bakke A, Mdala I, Nokleby K, et al. Exploring the relationship between coronary heart disease and type 2 diabetes: a cross-sectional study of secondary prevention among diabetes patients. BJGP Open. 2019;3: bjgpopen18X101636. PubMed PMC

McGurnaghan S, Blackbourn LAK, Mocevic E, Haagen Panton U, McCrimmon RJ, Sattar N, et al. Cardiovascular disease prevalence and risk factor prevalence in type 2 diabetes: a contemporary analysis. Diabet Med. 2019;36:718–725. doi: 10.1111/dme.13825. PubMed DOI PMC

Franch-Nadal J, Mata-Cases M, Vinagre I, Patitucci F, Hermosilla E, Casellas A, et al. Differences in the cardiometabolic control in type 2 diabetes according to gender and the presence of cardiovascular disease: results from the eControl study. Int J Endocrinol. 2014;2014:131709. doi: 10.1155/2014/131709. PubMed DOI PMC

Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17:83. doi: 10.1186/s12933-018-0728-6. PubMed DOI PMC

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194. doi: 10.1001/jama.2013.281053. PubMed DOI

Guidelines for Good Pharmacoepidemiology Practices (GPP) https://www.pharmacoepi.org/resources/policies/guidelines-08027/.

American Diabetes Association 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43:S111–34. doi: 10.2337/dc20-S010. PubMed DOI

Trulicity® Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125469s023lbl.pdf. Accessed 24 June 2021.

Victoza® Prescribing Information https://www.novo-pi.com/victoza.pdf. Accessed 24 June 2021.

Invokana® Prescribing Information http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVOKANA-pi.pdf. Accessed 24 June 2021.

Farxiga® Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202293s003lbl.pdf. Accessed 24 June 2021.

Jardiance® Prescribing Information https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf. Accessed 24 June 2021.

Ozempic® Prescribing Information [https://www.novo-pi.com/ozempic.pdf]. Accessed 24 June 2021.

International Diabetes Federation: IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation; 2017.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–130. doi: 10.1016/S0140-6736(19)31149-3. PubMed DOI

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380:347–357. doi: 10.1056/NEJMoa1812389. PubMed DOI

Barquera S, Pedroza-Tobías A, Medina C, Hernández-Barrera L, Bibbins-Domingo K, Lozano R, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res. 2015;46:328–338. doi: 10.1016/j.arcmed.2015.06.006. PubMed DOI

Schütte S, Acevedo PNM, Flahault A. Health systems around the world—a comparison of existing health system rankings. J Glob Health. 2018;8:010407. doi: 10.7189/jogh.08.010407. PubMed DOI PMC

World Health Organization (WHO) Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization; 2011.

Boonman-de Winter LJM, Rutten FH, Cramer MJM, Landman MJ, Liem AH, Rutten GEHM, Hoes AW. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55(8):2154–2162. doi: 10.1007/s00125-012-2579-0. PubMed DOI PMC

World Health Organization (WHO) A Prioritized Research Agenda for Prevention and Control of Noncommunicable Diseases. Geneva: World Health Organization; 2011.

Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res. 2017;121:677–694. doi: 10.1161/CIRCRESAHA.117.308903. PubMed DOI

Schnell O, Erbach M, Hummel M. Primary and secondary prevention of cardiovascular disease in diabetes with aspirin. Diab Vasc Dis Res. 2012;9:245–255. doi: 10.1177/1479164112441486. PubMed DOI

Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860. doi: 10.1016/S0140-6736(09)60503-1. PubMed DOI PMC

Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. doi: 10.1016/S0140-6736(10)61350-5. PubMed DOI PMC

Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group

Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study

The Role of Physicians' Digital Tools in Pharmacological Management of Type 2 Diabetes Mellitus

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03786406, NCT03811288, NCT03786406